1. Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial
- Author
-
James McGowan, Christopher Wiltrout, Howard Seltman, James F. Luther, Amy Yang, Dorothy Sit, Katherine L. Wisner, Jody D. Ciolino, Rasim Somer Diler, John Jesse Dills, Michael Terman, and Stephen R. Wisniewski
- Subjects
Light therapy ,medicine.medical_specialty ,medicine.medical_treatment ,Placebo-controlled study ,Placebo ,medicine.disease ,030227 psychiatry ,03 medical and health sciences ,Psychiatry and Mental health ,0302 clinical medicine ,Mood ,Hypomania ,Internal medicine ,mental disorders ,medicine ,sense organs ,Bipolar disorder ,medicine.symptom ,Psychiatry ,Psychology ,Mania ,Atypical depression ,030217 neurology & neurosurgery - Abstract
Objective:Patients with bipolar disorder have recurrent major depression, residual mood symptoms, and limited treatment options. Building on promising pilot data, the authors conducted a 6-week randomized double-blind placebo-controlled trial to investigate the efficacy of adjunctive bright light therapy at midday for bipolar depression. The aims were to determine remission rate, depression symptom level, and rate of mood polarity switch, as well as to explore sleep quality.Method:The study enrolled depressed adults with bipolar I or II disorder who were receiving stable dosages of antimanic medication (excluding patients with hypomania or mania, mixed symptoms, or rapid cycling). Patients were randomly assigned to treatment with either 7,000-lux bright white light or 50-lux dim red placebo light (N=23 for each group). Symptoms were assessed weekly with the Structured Interview Guide for the Hamilton Depression Scale With Atypical Depression Supplement (SIGH-ADS), the Mania Rating Scale, and the Pittsburg...
- Published
- 2018
- Full Text
- View/download PDF